Retrospective study of Salvage immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) combination therapy for metastatic renal cell carcinoma

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Avelumab (Primary) ; Axitinib (Primary) ; Cabozantinib (Primary) ; Ipilimumab (Primary) ; Lenvatinib (Primary) ; Nivolumab (Primary) ; Pazopanib (Primary) ; Pembrolizumab (Primary) ; Sunitinib (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use

13 Sep 2021 Results presented at the 116th Annual Meeting of the American Urological Association
28 Jul 2021 New trial record
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com